提高D-二聚体的临界值对评估肺癌患者预后的价值

doi:10.3969/j.issn.1673-8640.2020.08.005

检验医学 ›› 2020, Vol. 35 ›› Issue (8): 763-766.DOI: 10.3969/j.issn.1673-8640.2020.08.005

提高D-二聚体的临界值对评估肺癌患者预后的价值

刘勤¹, 陈冲², 岳超³

1. 天津市第五中心医院检验科,天津 300450
2.天津医科大学肿瘤医院检验科,天津 300060
3.天津市第五中心医院输血科,天津 300450

收稿日期:2019-07-23 出版日期:2020-08-30 发布日期:2020-09-24
作者简介:null
作者简介：刘勤,女,1984年生,硕士,技师,主要从事医学检验指标对肿瘤检测的价值分析研究。

Role of an elevated D-dimer cut-off value for the prognosis of lung cancer

LIU Qin¹, CHEN Chong², YUE Chao³

1. Department of Clinical Laboratory,Tianjin No.5 Central Hospital,Tianjin 300450,China
2. Department of Clinical Laboratory,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,China
3. Department of Blood Transfusion,Tianjin No.5 Central Hospital,Tianjin 300450,China

Received:2019-07-23 Online:2020-08-30 Published:2020-09-24

摘要/Abstract

摘要：

目的分析提高D-二聚体（DD）的临界值对评估肺癌患者预后的价值。方法随访记录153例肺癌患者生存期和实验室指标,在化疗或手术前检测癌胚抗原（CEA）、细胞角蛋白19片段（CYFRA21-1）、乳酸脱氢酶（LDH）、鳞状细胞癌抗原（SCC-Ag）、DD,并对检测结果进行统计分析。结果不同性别、年龄、CEA、CYFRA21-1、LDH、DD的肺癌患者生存期无明显差异（P>0.05）,而将DD的临界值提高至981 ng/mL,DD高含量组（≥981 ng/mL）生存期明显低于低含量组（P<0.05）。结论提高DD的临界值至981 ng/mL可有效评估肺癌患者预后。

关键词: 肺癌, D-二聚体, 临界值, 生存期

Abstract:

Objective To investigate the role of an elevated D-dimer（DD） cut-off value for the prognosis of lung cancer. Methods The clinical and laboratory data of 153 patients with lung cancer were studied retrospectively. Carcinoembryonic antigen（CEA）,cytokeratin-19 fragment（CYFRA21-1）,lactate dehydrogenase（LDH）,squamous cell carcinoma antigen（SCC-Ag） and DD were determined before chemotherapy or surgery,and the results were analyzed statistically. Results There was no statistical significance for overall survival rate between different sex,age,CEA,CYFRA21-1,LDH and DD（P>0.05）. The overall survival rate in high DD（≥981 ng/mL） group was lower than that in normal DD（<981 ng/mL） group（P<0.05）. Conclusions The elevated DD cut-off value to 981 ng/mL is beneficial to prognosis prediction in lung cancer.

Key words: Lung cancer, D-dimer, Cut-off value, Overall survival

中图分类号:

R446.1

刘勤, 陈冲, 岳超. 提高D-二聚体的临界值对评估肺癌患者预后的价值[J]. 检验医学, 2020, 35(8): 763-766.

LIU Qin, CHEN Chong, YUE Chao. Role of an elevated D-dimer cut-off value for the prognosis of lung cancer[J]. Laboratory Medicine, 2020, 35(8): 763-766.

图/表 3

参考文献 17

[1]	HISADA Y,GEDDINGS J E,AY C,et al. Venous thrombosis and cancer:from mouse models to clinical trials[J]. J Thromb Haemost,2015,13(8):1372-1382.
[2]	HANNA D L,WHITE R H,WUN T. Biomolecular markers of cancer-associated thromboembolism[J]. Crit Rev Hematol,2013,88(1):19-29.
[3]	ELYAMANY G,ALZAHRANI A M,BUKHARY E. Cancer-associated thrombosis:an overview[J]. Clin Med Insights Oncol,2014,8:129-137.
[4]	SEAMAN S,NELSON A,NOBLE S. Cancer-associated thrombosis,low-molecular-weight heparin,and the patient experience:a qualitative study[J]. Patient Prefer Adherence,2014,8:453-461.
[5]	ZHU L R,LI J,CHEN P,et al. Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients[J]. Clin Transl Oncol,2016,18(2):178-188.
[6]	FEI X,WANG H,JIANG L,et al. Clinical and prognostic significance of lupus anticoagulant measurement in patients with lung cancer[J]. Technol Cancer Res Treat,2017,16(6):1006-1013.
[7]	MEGO M,ZUO Z,GAO H,et al. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer[J]. Thromb Haemost,2015,113(3):593-598.
[8]	LIU L,ZHANG X,YAN B,et al. Elevated plasma D-dimer levels correlate with long term survival of gastric cancer patients[J]. PLoS One,2014,9(3):e90547.
[9]	FAN S,ZHAO G,AN G. High pretreatment plasma D-dimer levels are associated with shorter overall survival in patients with small cell lung cancer[J]. J Int Med Res,2019,47(1):215-224.
[10]	GO S I,LEE M J,LEE W S,et al. D-dimer can serve as a prognostic and predictive biomarker for metastatic gastric cancer treated by chemotherapy[J]. Medicine(Baltimore),2015,94(30):e951.
[11]	GAO X L,WANG S S,CAO D B,et al. The role of plasma D-dimer levels for predicting lymph node and mediastinal lymph node involvement in non-small cell lung cancer[J]. Clin Respir J,2018,12(6):2151-2156.
[12]	KWIETNIAK M,AL-AMAWI T,BASZKOWSKI T,et al. The usefulness of D-dimer in diagnosis and prediction of venous thromboembolism in patients with abdominal malignancy[J]. Pol Przegl Chir,2017,89(3):27-30.
[13]	CHEN C,LI G,LIU Y D,et al. A new D-dimer cutoff value to improve the exclusion of deep vein thrombosis in cancer patients[J]. Asian Pac J Cancer Prev,2014,15(4):1655-1658.
[14]	HONG T,SHEN D,CHEN X,et al. Preoperative plasma fibrinogen,but not D-dimer might represent a prognostic factor in non-metastatic colorectal cancer:a prospective cohort study[J]. Cancer Biomark,2017,19(1):103-111.
[15]	WANG Y,WANG Z. Predictive value of plasma D-dimer levels in patients with advanced non-small-cell lung cancer[J]. Onco Targets Ther,2015,8:805-808.
[16]	ALEXANDER M,WOLFE R,BALL D,et al. OC-05-D-dimer,fibrinogen and TEG-MA predict thromboembolism in non-small cell lung cancer-interim results from a prospective cohort study[J]. Thromb Res,2016,140(Suppl 1):S170.
[17]	WILTS I T,LE GAL G,DEN EXTER P L,et al. Performance of the age-adjusted cut-off for D-dimer in patients with cancer and suspected pulmonary embolism[J]. Thromb Res,2017,152:49-51.

提高D-二聚体的临界值对评估肺癌患者预后的价值

Role of an elevated D-dimer cut-off value for the prognosis of lung cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 17

相关文章 15

编辑推荐

Metrics

[1]	周韵斓, 沈立松. 液体活检标志物在非小细胞肺癌中的临床应用和挑战[J]. 检验医学, 2023, 38(9): 807-811.
[2]	朱日祥, 殷杰. 可溶性生长刺激表达基因2蛋白与结直肠癌患者临床病理特征和预后的关系[J]. 检验医学, 2023, 38(7): 629-633.
[3]	陈颖, 李伟, 林涛, 杨丽. PFTK1表达与非小细胞肺癌微血管密度和患者预后的关系[J]. 检验医学, 2023, 38(7): 634-639.
[4]	杨忠信, 李晓宇, 陈涛, 曹文军. IL-8和MMP-2在非小细胞肺癌患者胸腔镜肺段切除术预后评估中的价值[J]. 检验医学, 2023, 38(4): 342-346.
[5]	宋世伟, 李景武, 林韬, 刘泽宇, 王志强, 孙卫东. GPNMB与非小细胞肺癌患者肿瘤免疫浸润和预后的相关性[J]. 检验医学, 2023, 38(4): 347-351.
[6]	张嘉懿, 郭文伟, 沈永明, 娜仁, 崔小健, 司萍. 光激化学发光法检测儿童乙型肝炎核心抗体最佳临界值探讨[J]. 检验医学, 2023, 38(3): 291-293.
[7]	顾玉, 梁晓艳, 马胜辉, 佟娜, 程明艳, 阎泽君. 血浆生物标志物在慢性肾脏病伴血栓栓塞患者中的表达及其近期预后评估价值[J]. 检验医学, 2023, 38(12): 1177-1182.
[8]	柳行强, 宁立芬, 李琳, 陈忠成. FR⁺-CTC、ANXA2、ProGRP与肺癌临床病理特征的相关性[J]. 检验医学, 2022, 37(8): 735-740.
[9]	赵明娜, 张宸梓, 洪秋双, 娄加陶. IL-8/miR-182正反馈调控轴在非小细胞肺癌中的作用机制研究[J]. 检验医学, 2022, 37(4): 349-355.
[10]	王建英, 王珊珊, 朱俊, 黄晓春, 万玉香, 刘云. 肺癌患者化疗后肺部感染病原菌分布及耐药性分析[J]. 检验医学, 2022, 37(4): 356-359.
[11]	纪伟, 田国力, 朱之星, 周卓, 王燕敏, 张潇分. 间接法建立上海地区新生儿G6PD筛查临界值的可行性[J]. 检验医学, 2022, 37(2): 112-116.
[12]	成景松, 阮家安, 孟建华. 血浆DD联合GRACE评分在老年急性心肌梗死预后评估中的价值[J]. 检验医学, 2022, 37(2): 162-164.
[13]	徐润灏, 邹琛, 曹芸, 陈风, 刘怡菁, 张舒林, 张洁. 早期非小细胞肺癌患者血清氨基酸检测的临床意义[J]. 检验医学, 2022, 37(12): 1157-1163.
[14]	吴文萍, 徐林娟, 王佳亨, 张娜娜. PBK/TOPK表达与老年急性髓系白血病患者治疗反应和生存预后的关联分析[J]. 检验医学, 2022, 37(11): 1017-1022.
[15]	徐志刚, 卢霞, 龚晓霖. CA125、Fib、DD在卵巢癌化疗疗效评估中的价值[J]. 检验医学, 2022, 37(11): 1104-1105.